Non-Invasive Prenatal Testing Market Determines the Growth of Screening Programs at Births

The Global Non-Invasive Prenatal Testing Market was worth USD 1.46 billion in 2016 and is projected to be growing at a CAGR of 15.6%, to touch USD 3.01 billion by 2021

Logo

Hyderabad, India -- (SBWire) -- 03/05/2018 --Market Data Forecast has announced the addition of the "Non-Invasive Prenatal Testing Market By Instruments (Ultrasound, NGS, PCR, Microarray), Method (FCMB, Cf-DNA), By Application (Trisomy, Microdeletion, Genetics, Rh Factor), By End User (Hospital, Diagnostic Labs) And By Region - Global Industry Analysis, Size, Share, Growth, Trends, And Forecasts (2016–2021)" report to their offering. The market is expected to grow at a steady rate of 15.6% over the forecasting period of 2016-2021, that will take the market from USD 1.46 billion in 2016 to USD 3.01 billion by 2021.

The gender of a fetus may be identified by using NIPT. Non-Invasive Prenatal Testing (NIPT) is used for the genetic test in order to find whether there are any hereditary diseases and birth defects in the fetus. This Non-Invasive Prenatal Testing is employed in order to analyze the DNA, blood screening is done and that is referred as cell-free DNA (Cf-DNA) to accurately estimate a baby's risk for a spread of genetic disorders, and also used to spot the foremost common body anomalies like Edwards Syndrome (Trisomy 18), Patau Syndrome (Trisomy 13) and birth defect (Trisomy 21). Nuchal translucence (NT) scans, Amniocentesis, maternal humor screening, villus sampling (CVS) are the first diagnostic and screening strategies for body abnormalities.

View Report Page: https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/

The Global Non-Invasive Prenatal Testing market is majorly driven by factors are increasing the risk of body abnormalities in babies, the rise in the acceptance of NIPT, developing a number of advanced NIPT products, favourable compensation for NIPT, Growth of screening programs at births, growing preference for non-invasive techniques over invasive ones.
However, particularly in the Microdeletion segment, the possibility of false positives tied with the lower clinical validity is impeding the growth of the Non-Invasive Prenatal Testing market.

Request For Sample@ https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/request-sample

The segmentation of Global Non-Invasive Prenatal Testing market is done on the basis of instruments, end-users, application, and method of screening. On the idea of end-users, the Non-Invasive Prenatal Testing market is classified as hospitals and diagnostic labs. On the origin of application, the market is bifurcated into Rh factor, Trisomy, Genetics, and Microdeletion. On the source of instruments, the world wide Non-Invasive Prenatal Testing market is divided into PCR, Ultrasound, Microarray, and NGS. On the basis of the method of screening, the market is categorized as FCMB and cf-DNA.

Customized Report: https://www.marketdataforecast.com/market-reports/non-Invasive-prenatal-testing-market-2818/customize-report

On the standard of geographical analysis, the worldwide Non-Invasive Prenatal Testing market is classified into varied regions namely Middle East, North America, Europe, Latin America, and Asia-Pacific, Africa. In 2016, the market is lead by North America along with the U.S holds an important share. North America is leading the market in high-end technology that is merged with the rising incidence of genetic abnormalities and it is followed by Europe because of the increasing awareness about NIPT procedures. Because of the larger population numbers, Asia-Pacific is computable to grow at the best CAGR throughout the forecast period.

Some of the prominent firms dominating the market are F. Hoffmann-La Roche Ltd. (Switzerland), GE Healthcare (U.S.), Beijing Genomics Institute (China), Thermo Fisher Scientific, Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), PerkinElmer, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Germany), Pacific Biosciences of California, Inc. (U.S.).

Scope of the report
The report offers a comprehensive analysis of the industry by providing the estimations of market potential and forecasts with utmost granularity. Along this, the factors influential in effecting the market dynamics and trends are discussed in detail at the product level. Further, the performance of the market at the regional and country-level is assessed and the prospects with high growth potential are identified and debated.
The key players in the industry are profiled providing insights on their financial performance, market position and growth strategies. Comparative analysis on prime strategical activities of the market players delineating the key developments like mergers & acquisitions, collaborations and an evaluation of the competitive environment within the industry are provided. The report also offers a broad outlook of the market along with recommendations from industry experts on the opportunities for investment activity.
What else? Apart from the syndicated report, our in-house team has an expertise and experience in designing custom reports to meet your specific research needs and assist you in making well-informed decisions.

Contact Info:
Name: Mr. Abhishek Shukla
Email: abhishek@marketdataforecast.com
Organization: MarketDataForecast™
Address: 2nd Floor, Lakeview Plaza, Kavuri Hills, Hyderabad, Telangana 500033, India.
Phone: +1-888-702-9626

Media Relations Contact

Sai Kutumbarao
Business Development Executive
Market Data Forecast
1-888-702-9626
http://www.marketdataforecast.com/

View this press release online at: http://rwire.com/940444